Actinomycin D: Clinical Trials

4 trials of Actinomycin D, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 active not recruiting, 1 recruiting. 4 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 24Completed 2, Active not recruiting 1, Recruiting 1
Phase 11Recruiting 1

Follow Actinomycin D: new trials by email Literature Review of Actinomycin D trials Research Report on Actinomycin D

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evolutionary Therapy for Rhabdomyosarcoma
Vincristine, Cyclophosphamide, Vinorelbine - Rhabdomyosarcoma
Phase 2Active not recruitingH. Lee Moffitt Cancer Center and Research Institute122020-12-292025-11-26
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
Irinotecan, Actinomycin D, Doxorubicin - Rhabdomyosarcoma
Phase 1 / Phase 2RecruitingUniversity of Birmingham16722020-09-172024-05-23
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
Cixutumumab, Cyclophosphamide, Dactinomycin - Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma
Phase 2CompletedNational Cancer Institute (NCI)1752010-01-012017-08-29
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
filgrastim, cisplatin, cyclophosphamide - Central Nervous System Tumor, Pediatric
Phase 2CompletedDana-Farber Cancer Institute252003-02-012015-12-24

Conditions studied

Rhabdomyosarcoma (3)  ·  Sarcoma (2)  ·  Central Nervous System Neoplasms (1)  ·  Rhabdoid Tumor (1)

Sponsors

Dana-Farber Cancer Institute (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  National Cancer Institute (NCI) (1)  ·  University of Birmingham (1)

Countries

United States (3)  ·  Australia (2)  ·  New Zealand (2)  ·  Austria (1)  ·  Belgium (1)  ·  Canada (1)  ·  Czechia (1)  ·  Denmark (1)  ·  France (1)  ·  Greece (1)  ·  Ireland (1)  ·  Israel (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Norway (1)

Top investigators

Jonathan Metts, MD (1)  ·  Mark W. Kieran, MD, PhD (1)  ·  Meriel Jenney (1)  ·  Suman Malempati, MD (1)

Results publications

PMID 19064966

NIH funding

2018 (1), P30CA006516 (1), U10CA098543 (1), U10CA180886 (1)